[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Masonic Cancer Center, University of Minnesota\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":674},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,37,0,25,[9,75,105,126,158,182,206,231,253,275,300,321,369,393,414,436,456,475,502,523,543,565,588,618,646],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":55,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100309946","phase-2-myeloablative-allo-hsct-with-related-or-unrelated-donor-for-heme-disorders-100309946",false,"NCT03314974","Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases","-Inclusion Criteria:\n\n* Age: ≤ 60 years of age\n* Performance Status: Karnofsky ≥ 70%, Lansky play score ≥ 70\n* Consent: Voluntary written consent (adult or legally authorized representative; or parental\u002Fguardian)\n* Adequate Organ Function:\n\n  * Renal: Creatinine \\\u003C2x upper limit of normal. Patients above this limit must have creatinine clearance ≥ 40 ml\u002Fmin\u002F1.73m2 as determined by an age-appropriate method, such as cystatin C GFR.\n  * Hepatic: Bilirubin, AST, alkaline phosphatase \\\u003C4 times the upper limit of institutional normal\n  * Pulmonary: Diffusion capacity of oxygen, corrected for hemoglobin, \\> 50% of predicted. For pediatric patients not able to undergo PFTs or diffusion testing: O2 sat of \\>95% on room air\n  * Cardiac: Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction \\> 45%. For children not able to cooperate with MUGA or echocardiography, such should be clearly stated in the physician's documentation\n  * HIV Status: HIV infection with undetectable viral load. All HIV+ patients must be evaluated by Infectious Disease (ID) and a HIV management plan establish prior to transplantation\n\nOther Inclusion Criteria:\n\n* Women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment.\n* Donor Availability: Patients considered for transplantation must have a sufficient graft as based on current criteria of the University of Minnesota Blood and Marrow Transplantation Program\n* Eligible Diseases and Status: Patients are eligible unless their treatment is to be guided by a higher priority protocol.\n* Acute Leukemias: Must be in remission by morphology (≤5% blasts). Also a small percentage of blasts that is equivocal between marrow regeneration vs. early relapse are acceptable provided there are no associated cytogenetic markers consistent with relapse.\n* Acute Myeloid Leukemia (AML) and related precursor neoplasms: 2nd or greater complete remission (CR); first complete remission (CR1) in patients \\> 60 years old; CR1 in ≤ 60 years old that is NOT considered as favorable-risk.\n* Favorable risk AML is defined as having one of the following:\n\n  * t(8,21) without cKIT mutation\n  * inv(16) or t(16;16) without cKIT mutation\n  * Normal karyotype with mutated NPM1 and wild type FLT-ITD\n  * Normal karyotype with double mutated CEBPA\n  * Acute prolymphocytic leukemia (APL) in first molecular remission at the end of consolidation\n* Very high risk pediatric patients with AML: Patients \\\u003C21 years, however, are eligible with (M2 marrow) with \\\u003C 25% blasts in marrow after having failed one or more cycles of chemotherapy.\n* Acute lymphoblastic leukemia (ALL)\u002Flymphoma: second or greater CR; CR1 unable to tolerate consolidation chemotherapy due to chemotherapy-related toxicities; CR1 high-risk ALL.\n* High risk ALL is defined as having one of the following:\n\n  * Evidence of high risk cytogenetics, e.g. t(9;22), t(1;19), t(4;11), other MLL rearrangements, IKZF1\n  * 30 years of age or older at diagnosis\n  * White blood cell counts of greater than 30,000\u002FmcL (B-ALL) or greater than 100,000\u002FmcL (T-ALL) at diagnosis\n  * CNS leukemia involvement during the course of disease\n  * Slow cytologic response (\\>10% lymphoblasts in bone marrow on Day 14 of induction therapy)\n  * Evidence of persistent immonophenotypic or molecular minimal residual disease (MRD) at the end of induction and consolidation therapy\n* Very high risk pediatric patients with ALL: patients \\\u003C21 years are also considered high risk CR1 if they had M2 or M3 marrow at day 42 from the initiation of induction or M3 marrow at the end of induction. They are eligible once they achieve a complete remission.\n* Chronic Myelogenous Leukemia excluding refractory blast crisis: To be eligible in first chronic phase (CP1) patient must have failed or be intolerant to one or more tyrosine kinase inhibitors.\n* Plasma Cell Leukemia after initial therapy, in patients who have achieved at least a partial remission\n* Myeloproliferative Neoplasms\u002FMyelofibrosis, either primary as a result of polycythemia vera or essential thrombocythemia, with disease risk of intermediate or high-risk according to DIPSS criteria. Blasts must be \\\u003C10% by bone marrow aspirate morphology.\n* Myelodysplasia (MDS) IPSS INT-2 or High Risk (i.e. RAEB, RAEBt) or Refractory Anemia with severe pancytopenia, transfusion dependence, or high risk cytogenetics or molecular features. Blasts must be \\\u003C 10% by a representative bone marrow aspirate morphology.\n* Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL), Marginal Zone B-Cell Lymphoma or Follicular Lymphoma are eligible if there was disease progression\u002Frelapse within 12 of achieving a partial or complete remission. Patients who had remissions lasting \\> 12 months, are eligible after at least two prior therapies. Patients with bulky disease (nodal mass greater than 5 cm) should be considered for debulking chemotherapy before transplant.\n* Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia are eligible after initial therapy in CR1+ or PR1+.\n* Diffuse large Cell NHL \\> CR\u002F\\> PR: Patients in CR\u002FPR with initial short remission (\\\u003C6 months) are eligible, or those who have failed\u002For are not eligible for autologous transplant.\n* Lymphoblastic Lymphoma, Burkitt's Lymphoma, and other high-grade NHL after initial therapy if stage III\u002FIV in CR1\u002FPR1 or after progression if stage I\u002FII \\\u003C 1 year.\n* Multiple Myeloma beyond PR2: Patients with chromosome 13 abnormalities, first response lasting less than 6 months, or β-2 microglobulin \\> 3 mg\u002FL, may be considered for this protocol after initial therapy.\n* Juvenile myelomonocytic leukemia\n* Biphenotypic\u002FUndifferentiated\u002FProlymphocytic Leukemias in first or subsequent CR.\n* MRD positive leukemia (AML, ALL or accelerated\u002Fblast phase CML). Selected patients in morphologic CR, but with positive immunophenotypic (flow cytometry) or molecular evidence of MRD may be eligible if recent chemotherapy has not resulted in MRD negative status.\n* Natural Killer Cell Malignancies\n* Acquired Bone Marrow Failure Syndromes except for Fanconi Anemia or Dyskeratosis Congenita\n* Other Leukemia Subtypes: A major effort in the field of hematology is to identify patients who are of high risk for treatment failure so that patients can be appropriately stratified to either more (or less) intensive therapy. This effort is continually ongoing and retrospective studies identify new disease features or characteristics that are associated with treatment outcomes. Therefore, if new features are identified after the writing of this protocol, patients can be enrolled with the approval of two members of the study committee.\n\nExclusion Criteria:\n\n* Chemotherapy refractory large cell and high grade NHL (i.e., progressive disease after \\> 2 salvage regimens)\n* CML in blast crisis\n* Large cell lymphoma, mantle cell lymphoma and Hodgkin disease that is progressing on salvage therapy.\n* Evidence of progressive disease by imaging modalities or biopsy - persistent PET activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of CT changes indicating progression.\n* Active central nervous system malignancy\n* if ≤ 18 years old, prior myeloablative transplant within the last 6 months. If \\>18 years old prior myeloablative allotransplant or autologous transplant\n* Active HIV infection or known HIV positive serology\n* active uncontrolled infection\n* Pregnant or breastfeeding. The agents used in this study include Pregnancy Category D: known to cause harm to a fetus. Females of childbearing potential must have a negative pregnancy test prior to starting therapy.","ALL","60 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine\u002Fbusulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54],"Acute Leukemia","Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia","Lymphoma","Chronic Myelogenous Leukemia","Plasma Cell Leukemia","Myeloproliferative Neoplasms","Myelofibrosis","Myelodysplasia","Refractory Anemia","High Risk Anemia","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Marginal Zone B-Cell Lymphoma","Follicular Lymphoma","Lymphoplasmacytic Lymphoma","Mantle-Cell Lymphoma","Prolymphocytic Leukemia","Diffuse Large Cell Non Hodgkins Lymphoma","Lymphoblastic Lymphoma","Burkitt Lymphoma","High Grade Non-Hodgkin's Lymphoma, Adult","Multiple Myeloma","Juvenile Myelomonocytic Leukemia","Biphenotypic\u002FUndifferentiated\u002FProlymphocytic Leukemias","MRD Positive Leukemia","Natural Killer Cell Malignancies","Acquired Bone Marrow Failure Syndromes",[56,17,57,58,59,60,61],"AML","MDS","NHL","CLL","CML","SLL","RECRUITING","2026-06-23",{"date":65,"type":66},"2026-06-25","ACTUAL",{"date":68,"type":66},"2018-03-30",{"date":70,"type":21},"2028-06-10",{"name":72,"class":73},"Masonic Cancer Center, University of Minnesota","OTHER",1,{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100642375","gutcheck-optimization-of-a-personalized-mobile-health-app-for-survivors-of-gastrointestinal-cancer-100642375","NCT07661017","GutCheck: Optimization of a Personalized Mobile Health App for Survivors of Gastrointestinal Cancer","Inclusion\n\nSurvivors of GI cancer are eligible if they are:\n\n* ≥18 years old\n* reside in or have received cancer care in Minnesota\n* own a smartphone • consent to install the GutCheck app and discontinue diet tracking in other lifestyle apps (e.g., MyFitness, Fitbit, Noom).\n* are English-speaking\n* have received a GI cancer diagnosis (e.g., esophageal, gastric, colorectal, liver, pancreatic, etc)\n* At least 2 months post-cancer treatment\n\nInclusion criteria for oncology specialists (oncologists, advanced practice providers, nurses, dietitians, and patient navigators) include:\n\n* Have interacted with at least 1 cancer patient or survivor in the past month.\n* Have experience working with electronic health records (EHR).\n\nExclusion\n\n* Currently pregnant (Patient Study ONLY)\n* Pregnancy status may be self-reported by the participant.\n* Individuals who are postmenopausal, surgically sterile, or otherwise unable to become pregnant are not subject to this exclusion.\n* Active cancer or receiving treatment for another cancer.\n* Currently taking or has taken antibiotics in the last 3 months.\n* Diagnosis of inflammatory bowel disease (e.g., Crohn's Disease, ulcerative colitis), and\u002For celiac disease.\n* Involuntary weight loss of 10% or more of usual body weight within 6 months, or involuntary loss of 5% or more of usual body weight in 1 month.\n\nOncology specialists' exclusion criteria include:\n\n* Unable to participate in an interview",true,"18 Years",{"count":84,"type":21},200,[86],"NA","There are two components to the study: a patient and a clinician study. The clinician study will include one-hour semi-structured interviews with oncology specialists to identify facilitators and barriers to integrating digital diet interventions into the clinical workflow, and to understand their needs and preferences for digital diet interventions. The patient study aims to investigate initial feasibility, efficacy and acceptability of the GutCheck app and intervention. It will last 9 weeks and involves 2 study visits and 2 active phases with a transition week and optional transition visit between phases. During active phases, participants will be asked to use the GutCheck app every day. Prior to the first active phase, participants will go through informed consent and app training. The first active phase will last two weeks and will focus on tracking participants' diet, gastrointestinal (GI) symptoms, and stress. The data collected during the first active phase will be used to identify any potential trigger foods that may contribute to GI symptoms, but only if the participant reports experiencing GI symptoms. Between active phases, participants will have one Transition Week, where results from the first phase are given to the participants with the option to attend a Transition Week Visit. The second active phase will last four weeks and will involve the message intervention. A single-blind, micro-randomized trial design will be used to repeatedly randomize participants to different intervention combinations, determining both the timing and frequency of intervention message delivery throughout the day. Lastly, there will be an exit visit and interview within a week from the intervention to collect post-intervention measures and ask about the participant's experience with the GutCheck app.",[89,90,91,92,93,94,95],"Gastrointestinal","Mobile Health","Gastrointestinal Symptoms","Gut Health","Gastrointestinal Cancer","Survivorship","GI Cancer","NOT_YET_RECRUITING","2026-06-16",{"date":99,"type":66},"2026-06-22",{"date":101,"type":21},"2026-12",{"date":103,"type":21},"2030-06",{"name":72,"class":73},{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":81,"sex":17,"minAge":112,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":74},"100561036","rural-smoking-cessation-100561036","NCT06584929","Rural Smoking Cessation","Evaluating Population-Based Strategies for Rural Smoking Cessation","Inclusion Criteria:\n\n* ≥ 21 years\n* smoke ≥ 5 cigarettes per day\n* daily access to their own iPhone\u002FAndroid smartphone or tablet\n\nExclusion Criteria:\n\n* past 30-day NRT use or contraindications listed on the NRT labels\n* currently pregnant\u002Fbreastfeeding","21 Years",{"count":114,"type":21},272,[86],"Understanding ways to help people who live in rural areas quit smoking is a public health priority. quitting smoking among rural people who smoke is a critical public health concern. People in rural areas smoke at higher rates than those in urban areas, experience high rates of smoking caused cancers and deaths. We are recruiting rural people from around the country to better understand how different quit smoking methods can improve a person's chances of successfully quitting smoking.",[118],"Smoking Cessation",{"date":120,"type":66},"2026-06-18",{"date":122,"type":66},"2026-03-17",{"date":124,"type":21},"2029-08-31",{"name":72,"class":73},{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":17,"minAge":132,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":143,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":74},"100547786","phase-2-mt2023-20-hematopoietic-cell-transplant-with-reduced-intensity-conditioning-and-post-transplant-cyclophosphamide-for-severe-aplastic-anemia-and-other-forms-of-acquired-bone-marrow-failure-100547786","NCT06412497","MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","Inclusion Criteria:\n\n* Idiopathic Severe Aplastic Anemia (SAA), characterized by one of the following:\n\n  1. Refractory cytopenia(s), with 1+ of the following:\n\n     1. Platelets \\\u003C20,000\u002FuL or transfusion dependent\n     2. Absolute neutrophil count \\\u003C500\u002FuL without hematopoietic growth factor support\n     3. Absolute reticulocyte count \\\u003C60,000\u002FuL AND bone marrow cellularity \\\u003C50% (with \\\u003C 30% residual hematopoietic cells)\n  2. Early myelodysplastic features (bone marrow (BM) blasts \\\u003C5%), without history of MDS\u002FAML pre-treatment.\n  3. Idiopathic SAA with post-HCT graft failure (blood\u002Fmarrow donor chimerism \\\u003C5%) requiring a 2nd allogeneic HCT\n* Paroxysmal Nocturnal Hemoglobinuria (PNH), including AA-PNH overlap syndrome, acquired pure red cell aplasia (aPRCA), or acquired amegakaryocytic thrombocytopenia (aAT), characterized by one of the following:\n\n  1. Refractory cytopenia(s), with 1+ of the following:\n\n     1. Platelets \\\u003C20,000\u002FuL or transfusion dependent\n     2. Absolute neutrophil count \\\u003C500\u002FuL without hematopoietic growth factor support\n     3. Absolute reticulocyte count \\\u003C60,000\u002FuL or red cell transfusion dependent AND Bone marrow evidence of 1 to 3-lineage aplasia OR peripheral blood PNH clone \\>\u002F= 10%\n  2. Early myelodysplastic features (bone marrow (BM) blasts \\\u003C5%) without history of MDS\u002FAML pre-treatment.\n  3. Idiopathic PNH, aPRCA, or aAT with post-HCT graft failure (blood\u002Fmarrow donor chimerism \\\u003C5%) requiring a 2nd allogeneic HCT\n* Adequate organ function within 30 days of conditioning regimen\n\nExclusion Criteria:\n\n* Pregnant, breastfeeding or intending to become pregnant during the study. Persons of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days of the start of treatment\n* Uncontrolled infection\n* Evidence of moderate or severe portal fibrosis or cirrhosis on biopsy\n* Known allergy to any of the study components\n* Prior radiation therapy deemed excessive by radiation therapist for proposed low dose TBI exposure on this protocol\n* Diagnosis of an inherited bone marrow failure disorder such as Fanconi anemia, Telomere biology disorder, or Schwachman-Diamond syndrome, unless reviewed by the principal investigator and deemed appropriate for this approach (e.g. GATA2 deficiency)\n* Advanced myelodysplastic syndrome (MDS; BM blasts \\>5%) or acute myeloid leukemia\n* Psychiatric illness\u002Fsocial situations that, in the judgement of the enrolling Investigator, would limit compliance with study requirements\n* Other illness or a medical issue that, in the judgement of the enrolling Investigator, would exclude the patient from participating in this study","0 Years","75 Years",{"count":135,"type":21},60,[24],"A phase II trial of a reduced intensity conditioned (RIC) allogeneic hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) for idiopathic severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), acquired pure red cell aplasia (aPRCA), or acquired amegakaryocytic thrombocytopenia (aAT) utilizing population pharmacokinetic (popPK)-guided individual dosing of pre-transplant conditioning and differential dosing of low dose total body irradiation based on age, presence of myelodysplasia and\u002For clonal hematopoiesis.",[139,140,141,142],"Severe Aplastic Anemia","Acquired Amegakaryocytic Thrombocytopenia","Acquired Pure Red Cell Aplasia","Paroxysmal Nocturnal Hemoglobinuria",[144,145,146,147,148,149],"HCT","RIC","SAA","PTCy","aAT","aPRCA","2026-06-02",{"date":152,"type":66},"2026-06-03",{"date":154,"type":66},"2024-06-05",{"date":156,"type":21},"2036-05-01",{"name":72,"class":73},{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":81,"sex":17,"minAge":4,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":74},"100583131","phase-2-allo-hsct-for-high-risk-hemoglobinopathies-100583131","NCT06872333","Allo HSCT for High Risk Hemoglobinopathies","Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders","Inclusion Criteria:\n\n* Sickle Cell Disease (SCD)\n* SCD Patients with a fully matched sibling donor (MSD) irrespective of the frequency or severity of symptoms MSD transplant can be considered. Parents\u002Fpatient must be counseled as to the risks and benefits and provide their voluntary informed consent\n* Transfusion Dependent Alpha- or Beta- Thalassemia\n* Diamond Blackfan Anemia\n* Other Non-Malignant Hematologic Disorders\n* Karnofsky ≥ 60%, Lansky play score ≥ 60. Patients with lower performance score can be considered based on study team's evaluation.\n* Sexually active persons of childbearing potential or persons with partners of childbearing potential must agree to use a highly effective form of contraception during study treatment and for at least 4 months after the transplant.\n\nExclusion Criteria:\n\n* Pregnant, breastfeeding or intending to become pregnant during the study. Persons of childbearing potential must have a negative pregnancy test (serum or urine) within 30 days of the start of treatment\n* HIV infection with a detectable viral load. All HIV+ patients must be evaluated by infectious disease (ID) and an HIV management plan established prior to transplantation.\n* Active, uncontrolled infection - infection that is stable or improving after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections) will be permitted\n* Known allergy to any of the study components\n* Psychiatric illness\u002Fsocial situations that, in the judgement of the enrolling Investigator, would limit compliance with study requirements\n* Other illness or a medical issue that, in the judgement of the enrolling Investigator, would exclude the patient from participating in this study","55 Years",{"count":167,"type":21},62,[24],"A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.",[171,172,173],"Graft Failure","Sickle Cell Disease","Hemoglobinopathies","2026-06-01",{"date":176,"type":66},"2026-06-04",{"date":178,"type":66},"2024-11-19",{"date":180,"type":21},"2032-06-01",{"name":72,"class":73},{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":22,"phases":191,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":74},"100639057","phase-1-adapt-nk-for-high-risk-myeloid-diseases-as-bridge-to-allo-hsct-100639057","NCT07591649","Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT","Safety and Efficacy of Expanded KIR-HLA Mismatched Natural Killer Cell Immunotherapy (AdaptNK) for High-Risk Myeloid Diseases as Bridge to Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* 18-74 years with Karnofsky score ≥ 70%\n* 75 years and older: KPS ≥ 70%, HCT-CI \\\u003C 5 (excluding history of solid tumor), AND not frail by Fried frailty criteria (see Appendix III)\n* HLA type C1\u002FC1 or C2\u002FC2\n\nNote: For easy determination, the definition of HLA-C ligand group assigments is included below:\n\nHLA-C1 group alleles are defined as HLA-C01, C03, C07, C08, C12, C14, C16 HLA-C2 group alleles are defined as HLA-C02, C04, C05, C06, C15, C17, C18\n\n* adequate liver, renal, pulmonary and cardiac function\n* ability to be off glucocorticoids and other immunosuppressive medications indicated for acute or chronic GVHD for at least 28 days prior to the AdaptNK cell infusion\n* There must be sufficient time between the most recent therapy and the screening bone marrow as delineated below:\n* anti-leukemic systemic cytotoxic chemotherapy - 2 weeks\n* Targeted anti-leukemic agents (FLT-3, IDH, menin inhibitors) - 3 half-lives of the medication\n* Radiotherapy - 1 week\n* donor lymphocyte infusions - 6 weeks\n* hematopoietic growth factors (filgrastim, TPO agonists, EPO) - 1 week\n* biologic therapy (monoclonal antibodies, T-cell engagers) - 2 weeks\n* Immune effector cellular therapy - 4 weeks\n* Intrathecal chemotherapy for treatment of active CNS leukemia - there must be at least two CSF samples negative for leukemia separated by one week before enrollment.\n* WBC shall be \\\u003C 25,000 before infusion. Hydroxyurea is permitted until day -3 to control excess blast proliferation. No other systemic treatment is allowed after the screening bone marrow is performed for inclusion in protocol\n* All prior treatment related toxicities should have resolved to ≤ grade 1 prior to study enrollment\n* agrees to use of adequate contraception from study enrollment to 4 months after cell infusion\n* voluntary written consent\n\nExclusion Criteria:\n\n* Myeloid neoplasms with known or strongly suspected germline background, except DDX41, TP53, or RUNX1.\n* Acute promyelocytic leukemia (APL)\n* myocardial infarction (MI) within previous 6 months of study enrollment\n* pregnant or breastfeeding\n* Active CNS involvement with AML\n* new or progressive pulmonary infiltrates\n* active autoimmune disease requiring immunosuppressive therapy\n* Preexisting inflammatory disease requiring immunosuppressive therapy\n* history of severe asthma and currently on chronic systemic medications\n* HIV-1\u002F2 positivity or hepatitis C\u002FB\n* active systemic infections requiring anti-infective treatment\n* received any investigational agent within the 14 days before the start of study treatment (1st dose of fludarabine)\n* Patients with second malignancies are excluded if they have required systemic cytotoxic chemotherapy within 1 year or if they are not in remission\n* Exception: patients that are on stable dosing of hormonal therapy (e.g. aromatase inhibitor or antiandrogen therapy) for active breast or prostate cancer for 1 year are eligible.\n* Patients with excised basal cell or squamous cell carcinoma of the skin are eligible.\n* Patients with excised carcinoma in situ of the cervix or breast are eligible.\n* Patients with untreated T1a or T1b prostate cancer are eligible.",{"count":190,"type":21},18,[192,24],"PHASE1","This is a multi-institutional Phase I\u002FII study of an allogeneic KIR-HLA mismatched NK cell infusion (AdaptNK) and a short course of subcutaneous interleukin-2 (IL-2) administered after lymphodepleting chemotherapy \\[cyclophosphamide (CY)\u002Ffludarabine (FLU)\\] in patients with relapsed or refractory acute myelogenous leukemia (AML). AdaptNK is a natural killer (NK) cell product that is enriched for NK cells with an \"adaptive\", or human cytomegalovirus (CMV)-induced, phenotype.",[195,196,197],"Relapsed Adult AML","Refractory AML","Acute Myelogenous Leukemia","2026-05-15",{"date":200,"type":66},"2026-05-19",{"date":202,"type":66},"2026-05-08",{"date":204,"type":21},"2035-03-01",{"name":72,"class":73},{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":212,"targetDuration":214,"studyType":215,"phases":4,"briefSummary":216,"conditions":217,"keywords":221,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":74},"100346360","adrenoleukodystrophy-national-registry-study-100346360","NCT03789721","Adrenoleukodystrophy National Registry Study","Inclusion Criteria\n\n* Age 0 - 100\n* ALD patients or family member meeting any of the following criteria:\n\n  * Any patient diagnosed with ALD (confirmed by positive VLCFA testing and\u002For genetic mutation).\n  * Known or presumed mutation with ALD based on pedigree or confirmed mutation in ABCD1 gene\n* Participants living in the United States and territories\n\nExclusion Criteria\n\n* Patients diagnosed with ALD who lack the capacity to consent\u002Fassent AND do not have a designated legally authorized representative or guardian.\n* Patients who have undergone BMT or other cellular therapy .\n* Patients not fluent in English who are unable to consent in-person at the BMT Journey Clinic.\n* Patients who are illiterate\n* Patient determined by the PI or designee to be unlikely to complete required study components (due to language barriers, compliance issues, etc.)",{"count":213,"type":21},1000,"99 Years","OBSERVATIONAL","The aim of this registry to understand the natural history and disease progression in ALD and potentially develop bio-markers using the biospecimens collected using this registry.",[218,219,220],"ALD (Adrenoleukodystrophy)","Adrenoleukodystrophy","Cerebral Adrenoleukodystrophy",[222],"Registry, VLCFA, ABCD1, X-chromosome","2026-05-11",{"date":225,"type":66},"2026-05-12",{"date":227,"type":66},"2019-05-01",{"date":229,"type":21},"2030-02",{"name":72,"class":73},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":239,"briefSummary":240,"conditions":241,"keywords":244,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":74},"100167322","infusion-of-cell-populations-from-unlicensed-umbilical-cord-blood-units-100167322","NCT01451502","Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units","Inclusion Criteria:\n\nTo be eligible for an unlicensed umbilical cord blood (UCB) unit, the subject must meet each of the eligibility criteria listed below:\n\n* Subjects with any diagnosis for which there is an institutional review board (IRB) approved treatment protocol that requires UCB as a source of hematopoietic stem cells for lympho-hematopoietic reconstitution after myeloablative or non myeloablative conditioning.\n* Subject (or parent\u002Fguardian) must provide written informed consent for the use of unlicensed UCB units with co-enrollment onto a University of Minnesota IRB-approved clinical trial that details the disease specific treatment plan that prescribes the use of UCB as source of cells\n* Subject has an unlicensed UCB unit that meets required cell dose and HLA matching criteria (as defined in the primary treatment protocol) that is considered negative for tested blood-borne pathogens and also lack an 'equivalent', licensed UCB unit from a University of Minnesota approved Cord Blood Bank\n\nExclusion Criteria:\n\n* Exclusion criteria are specified in the treatment protocol according to indication.",{"count":238,"type":21},250,[86],"For the next 5-10 years or possibly longer, a high proportion of the Cord Blood Banks (CBB) inventory worldwide will be composed of unlicensed umbilical cord blood (UCB) units. While Food and Drug Administration (FDA)-licensed units will be prioritized, it will always be possible that an unlicensed unit will have known attributes, making it a better source of cells for the given indication. Because of the wide variety of current and potential indications as a source of cells for hematopoietic reconstitution or other form of cellular therapy, it is critical that the investigators have access to unlicensed UCB units.",[242,243],"Lymphatic Diseases","Hematopoietic Malignancy",[245],"umbilical cord blood","2026-05-07",{"date":202,"type":66},{"date":249,"type":66},"2011-10-20",{"date":251,"type":21},"2027-02",{"name":72,"class":73},{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":133,"enrollmentInfo":259,"targetDuration":4,"studyType":22,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":74},"100636067","phase-1-first-in-cancer-type-phase-i-study-of-ft536-for-recurrent-who-grade-4-astrocytoma-100636067","NCT07560865","First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma","Inclusion Criteria:\n\n* Histologically confirmed WHO Grade 4 astrocytoma from archival tissue. IDH mutation status and MGMT promoter methylation status will not limit candidacy but needs to be known.\n* Evidence of first or second cancer recurrence\u002F progression by magnetic resonance imaging (MRI) for which a gross tumor resection (GTR) is feasible as determined by the primary investigator in concordance with the study-affiliated neurosurgeon.\n* Previous completed SOC antitumor treatment including surgery, radiation therapy, and temozolomide +\u002F- Optune\u002F Tumor Treatment Fields (TTF).\n* No concurrent alternative curative therapy, including use of TTF.\n* Able to undergo standard MRI scans with contrast agent throughout the course of the study.\n* ≥ 18 years and ≤ 75 years of age at the time of consent.\n* Karnofsky performance status ≥70.\n* Must be completely off or on a dose of dexamethasone 2mg daily or less with stable neurological function at the time of enrollment.\n* Adequate organ function within 14 days of study treatment start as defined in Section 4.1.9 of the protocol.\n* Participants of childbearing potential (POCBP) or with partners of childbearing potential must use a highly effective form of contraception from the time of the screening visit until at least 3 months after the dose of FT536.\n* Must agree to and sign the consent for the companion Long-Term Follow-Up study (CPRC# 2021LS077).\n* Voluntary written consent prior to the performance of any research related procedures.\n* Agree to stay in the Twin Cities metropolitan area (i.e. within a 45-minute drive of the UMN) from the time of biopsy through hospital discharge following completion of the planned craniotomy.\n\nExclusion Criteria:\n\n* Clinically significant increased intracranial pressure (e.g., impending herniation or requirement for immediate palliative treatment) or uncontrolled seizures or any other situation requiring urgent neurosurgical intervention.\n* History of myelodysplastic syndrome (MDS)\u002F acute myeloid leukemia (AML) or with features suggestive of MDS\u002F AML.\n* Radiographic evidence of leptomeningeal disease.\n* Received prior treatment with bevacizumab or any other cellular therapy available on or off a clinical trial.\n* Non-malignant CNS disease such as CNS vasculitis or neurodegenerative disease.\n* Prior or current GammaTile, Gliadel wafer use, or other implanted therapeutic agent or photodynamic therapy.\n* Any known condition that requires systemic immunosuppressive therapy - inhaled and topical steroids are permitted.\n* Pregnant or breastfeeding. Menstruating POCBP must have a negative pregnancy test within 14 days before the planned biopsy. Patient must agree to use highly effective method of birth control from the time of the screening visit until at least 3 months after the dose of FT536.\n* Known seropositive for HIV or known Hepatitis B or C infection with detectable viral load by PCR.\n* Prior history of malignancy within 5 years of enrollment other than basal or squamous cell carcinoma of the skin, cervical intra-epithelial neoplasia, in situ carcinoma of the breast, or prostate cancer treated with surgery or RT with a prostate specific antigen of \\\u003C0.01 ng\u002FmL tested within 28 days of trial enrollment.\n* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pec",{"count":260,"type":21},9,[192],"This is a single center, first-in cancer-type phase I clinical trial of FT536 for adult patients with recurrent WHO Grade 4 astrocytoma, irrespective of IDH-mutational status, for which a standard of care repeat craniotomy for gross tumor resection at time of first or second recurrence is achievable. Per this treatment schema, FT536 will be administered once intratumorally",[264,265,266],"Astrocytoma","Glioblastoma","Progressive Disease","2026-04-24",{"date":269,"type":66},"2026-05-01",{"date":271,"type":66},"2026-04-23",{"date":273,"type":21},"2029-06-01",{"name":72,"class":73},{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":22,"phases":284,"briefSummary":285,"conditions":286,"keywords":290,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":74},"100634583","phase-1-gtb-5550-in-advanced-solid-tumors-100634583","NCT07541573","GTB-5550 in Advanced Solid Tumors","MT2025-14: A Phase 1a\u002F1b Study of GTB-5550, a Camelid Nanobody TriSpecific Killer Engager (camB7-H3 TriKE®), in Select Advanced Solid Tumors That Failed Prior Therapy","Inclusion Criteria:\n\n* Measurable disease per RECIST 1.1. (Exception: mCRPC limited to bone metastasis is exempt from this requirement).\n* Age 18 years or older at the time of consent, ECOG Performance Status 0 to 2\n* Acute effects of any prior therapy must have resolved to baseline or Grade ≤ 1 NCI CTCAE v5 except for AEs not constituting a safety risk in the opinion of the enrolling Investigator.\n* Adequate organ function within 14 days (30 days for cardiac) of Cycle 1 Day 1 defined as:\n* Hematologic: hemoglobin ≥ 9 g\u002FdL (may be transfused not more than 2 units of pRBCs within 7 days prior to Cycle 1 Day 1 to meet this requirement); absolute neutrophil count (ANC) ≥ 1500\u002Ful (granulocyte colonystimulating factor (s) is not allowed to achieve ANC threshold or within 7 days of Cycle 1 Day 1); platelets ≥ 100 x 10\\^9\u002FL (may be transfused not more than 2 units of platelets within 7 days prior to Cycle 1 Day 1 to meet this requirement); absolute lymphocyte count (ALC) ≥ 300\u002Ful.\n* Albumin ≥ 3.0 g\u002FdL.\n* Renal: a patient BSA corrected glomerular filtration rate ≥ 45 mL\u002Fmin as calculated using the Modified Cockroft-Gault equation (Rostoker et al. 2007).\n* Hepatic: AST and ALT ≤1.5 x upper limit of normal (ULN) and total bilirubin ≤1.5 x ULN.\n* Cardiac: New York Heart Association (NYHA) Class I or II ; left ventricular ejection fraction (LVEF) ≥ 45% by echocardiogram, MUGA, or cardiac MRI.\n* Adequate pulmonary function with PFTs \\> 50% FEV1 if symptomatic or known impairment.\n* Sexually active couples of childbearing-potential must agree to use effective contraception or abstinence during treatment and for at least 4 months after the final dose of GTB-5550.\n* Agrees to stay within a 60-minute drive of the study center through the Cycle 1 Day 15 visit for the Phase 1a study only.\n* Provides voluntary written consent prior to the performance of any research related activity\n\nExclusion Criteria:\n\n* Anti-cancer treatment including surgery, radiotherapy, chemotherapy, other immunotherapy, or investigational therapy within 14 days prior to the 1st dose of GTB-5550. Radioligand therapy requires at least 1 cycle washout (6 weeks for Pluvicto, 4 weeks for Xofigo).\n* Prior organ allograft or allogeneic transplantation. An exception is made for FA patients with prior history of allogeneic hematopoietic stem cell transplant off immune suppressive therapy for \\> 1 year.\n* Pregnant or breastfeeding or planning pregnancy within 4 months after the last dose of GTB-5550.\n* The potential risk of QT\u002FQTc prolongation is unknown in humans receiving GTB-5550; therefore, either of the following is an exclusion criteria: QTc interval \\> 480 msec at screening and\u002For a family history of long QT syndrome.\n* Prior malignancy other than the one under treatment except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer which is currently in complete remission, or any other cancer from which the patient has been disease-free for 1 year after surgical or other definitive treatment.\n* Active autoimmune disease that has required systemic treatment (except replacement therapy) within the past 1 year or any other diseases requiring immunosuppressive therapy while on study. Inhaled or topical steroids, and adrenal replacement steroid doses ≤10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\n* Active systemic infection requiring parenteral antibiotic therapy. Any prior systemic infections must have resolved to Grade 1 or lower following optimal therapy.\n* Psychiatric illness\u002Fsocial situations that in the judgement of the enrolling investigator would limit compliance with study requirements.\n* Other illness or a medical issue that, in the judgement of the enrolling Investigator, would exclude the patient's participation.",{"count":283,"type":21},175,[192],"This is a first-in-human Phase 1a\u002F1b trial of a B7-H3-targeted natural killer (NK) cell engager, referred to as a TriSpecific Killer Engager (TriKE), for the treatment of select solid tumor cancers. To be considered for the study, a patient must be 18 years or older, have histologically or cytologically confirmed advanced\u002Fmetastatic cancer that, based on literature reports, expresses B7-H3 at a high frequency, measurable disease by RECIST 1.1 (exception: mCRPC limited to bone metastasis are exempt from this requirement), meets the disease specific criteria for prior failed therapy, and refractory to, intolerant of, or ineligible for therapy options that are known to provide clinical benefit for their diagnosis.",[287,288,289],"Tri-specific Killer Engager","Solid Tumor","Advanced Solid Tumor",[291,292],"TriKE","GTB-5550","2026-04-20",{"date":271,"type":66},{"date":296,"type":66},"2026-04-08",{"date":298,"type":21},"2032-01",{"name":72,"class":73},{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":17,"minAge":306,"maxAge":133,"enrollmentInfo":307,"targetDuration":4,"studyType":22,"phases":309,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":74},"100630889","phase-2-mt2025-35-allogeneic-hematopoietic-stem-cell-transplantation-using-reduced-intensity-conditioning-treosulfan-and-fludarabine-with-post-transplant-cytoxan-ptcy-for-the-treatment-of-hematological-diseases-100630889","NCT07493538","MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases","Inclusion Criteria:\n\n* Patients 2-75 years of age\n* ≤7 5 years of age: Karnofsky score ≥ 70% (≥ 16 years) or Lansky play score ≥ 50 (\\\u003C 16 years) with appropriate organ criteria as below (in other inclusion criteria)\n* 5\u002F6 or 6\u002F6 related donor, OR a 5-8\u002F8 HLA-A, B, C, DRB1 allele match unrelated donor, OR a haplotype (at least 5\u002F10) related donor\n* adequate liver (no decompensated liver failure, Child Pugh A, AST\u002FALT \\\u003C5X ULN) and renal function (creatinine \\\u003C2.0)\n* absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction ≥ 40%\n* DLCO FEV1, FVC ≥ 40% predicted, and absence of O2 requirement\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Evidence of untreated\u002Funcontrolled HIV infection\n* Untreated active serious infection\n* Active CNS malignancy\n* CML in blast crisis not in a complete remission by abnormal blast count.\n* Less than 3 months since prior myeloablative transplant","2 Years",{"count":308,"type":21},132,[24],"This is a Phase II study following subjects proceeding with Treosulfan (36g\u002Fm2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide (PTCy) at 40mg\u002Fkg, tacrolimus and MMF for GVHD prophylaxis.",[56,57,27,28,312],"Myelodysplastic Syndromes","2026-04-13",{"date":315,"type":66},"2026-04-16",{"date":317,"type":66},"2026-04-10",{"date":319,"type":21},"2035-03",{"name":72,"class":73},{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":328,"targetDuration":4,"studyType":22,"phases":330,"briefSummary":331,"conditions":332,"keywords":349,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":74},"100495785","phase-2-mt2021-08t-cell-receptor-alphabeta-depletion-pbsc-transplantation-for-heme-malignancies-100495785","NCT05735717","MT2021-08T Cell Receptor Alpha\u002FBeta Depletion PBSC Transplantation for Heme Malignancies","Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha\u002FBeta Depletion (A\u002FB TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies","Inclusion Criteria:\n\n* Histological confirmation of hematological malignancies\n* Acute leukemias\n* Acute Myeloid Leukemia (AML) and related precursor neoplasms\n* Favorable risk AML is defined as having one of the following:\n* Acute lymphoblastic leukemia (ALL)\u002Flymphoma\n* Myelodysplasia (MDS) IPSS INT-2 or High Risk (i.e. RAEB, RAEBt) or Refractory Anemia with severe pancytopenia, transfusion dependence, or high risk cytogenetics or molecular features.\n* Age 60 years of age or younger at the time of consent\n* Karnofsky performance status ≥ 70% or Lansky play score 50% for ≤16 years of age.\n* Adequate organ function\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Active uncontrolled infection within 1 week of starting preparative therapy\n* Known seropositive for HIV or known active Hepatitis B or C infection with detectable viral load by PCR.\n* Any prior autologous or allogeneic transplant\n* CML blast crisis\n* Active central nervous system malignancy",{"count":329,"type":21},70,[24],"This is a phase II, open-label, prospective study of T cell receptor alpha\u002Fbeta depletion (TCR α\u002Fβ TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies. This is a safety\u002Ffeasibility study of the investigational procedure\u002Fproduct.",[333,27,334,28,29,56,335,336,337,338,339,35,50,340,341,342,343,344,345,346,347,348,46,48],"Hematologic Malignancy","Remission","TP53","Intrachromosomal Amplification of Chromosome 21","Cytogenetic Abnormality","CNS Leukemia","Minimal Residual Disease","Somatic Mutation","PTPN11 Gene Mutation","N-RAS Gene Amplification","Neurofibromatosis 1","NF1 Mutation","CBL Gene Mutation","Monosomy 7","Chromosome Abnormality","Fetal Hemoglobin",[350,351,352,353,354,144,355,356,357,358,359,360],"Bu","Flu","G-CSF","GFSR","aGVHD","MAC","Mel","PBSCT","PTLD","RECIST","TCR","2026-03-31",{"date":363,"type":66},"2026-04-06",{"date":365,"type":66},"2023-05-11",{"date":367,"type":21},"2030-11-30",{"name":72,"class":73},{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":81,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":74},"100488661","observational-study-of-exposure-to-environmental-toxicants-among-firefighters-100488661","NCT05643014","Observational Study of Exposure to Environmental Toxicants Among Firefighters","Evaluate the Exposure to Toxicants Emitted During a Structural Fire Assessed by Urinary and Buccal Cell Biomarkers Found in Firefighters.","Inclusion Criteria:\n\n* Firefighter (career or volunteer)\n* Over 18 years of age\n* Able to provide written voluntary consent\n\nExclusion Criteria:\n\n* Unwilling to provide a pre and post-exposure urine sample\n* Current cancer diagnosis\n* Tobacco use within the last 1 year (verified by urinary TNEs)",{"count":135,"type":21},"Observational, within subject study design with 1 pre and 2 post-fire exposure biomarker samples collected to assess exposure to toxicants from combustion emissions related to fighting a structural fire.",[379],"Healthy",[381,382,383,384],"PAH","1-HOP","PheT","SPMA","2026-03-10",{"date":387,"type":66},"2026-03-12",{"date":389,"type":66},"2020-02-01",{"date":391,"type":21},"2027-12-31",{"name":72,"class":73},{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":22,"phases":402,"briefSummary":403,"conditions":404,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":74},"100569298","phase-1-trial-of-cell-based-therapy-for-dmd-100569298","NCT06692426","Trial of Cell Based Therapy for DMD","Phase I Clinical Trial of Cell Based Therapy for Duchenne Muscular Dystrophy","Inclusion Criteria:\n\n* Duchenne muscular dystrophy, diagnosed by mutations in the DMD (dystrophin) gene and\u002For absence of immunohistochemical staining for dystrophin on muscle biopsy\n* Non-ambulatory\n* Intact extensor digitorum brevis (EDB) muscles bilaterally\n* Off investigational therapies for \\> 30 days\n* Age 18 years of age or older at the time of consent\n* Have adequate organ function confirmed by the following laboratory values obtained within 14 days prior to enrollment (28 days for cardiac and pulmonary function):\n* Participants with partners of childbearing potential must be willing to use at least two forms of effective birth control (one form must be a barrier method) while receiving the study product and for 3 months after stopping tacrolimus therapy.\n* Ability to follow commands sufficiently to perform voluntary aspects of outcome measures throughout the study period\n* Willing to consent to monitoring for 15 years, including an extension period, as required for all interventional studies involving the transplantation of cells that have been genetically modified\n* Voluntary written consent from the subject or parent(s)\u002Fguardian(s) and assent from participant prior to the performance of any research related activity.\n\nExclusion Criteria:\n\n* Presence of HLA antibodies directed toward HLA antigens on MyoPAXon\n* Active treatment with another investigational therapy\n* Known allergy to MyoPAXon components",{"count":401,"type":21},8,[192],"This is a single-center, single-arm, interventional phase 1 trial to evaluate the safety and tolerability of local injection of induced pluripotent stem cell (iPSC)- derived CD54+ allogeneic muscle progenitor cells in individuals with Duchenne muscular dystrophy (DMD)",[405],"Duchenne Muscular Dystrophy","2026-03-02",{"date":408,"type":66},"2026-03-04",{"date":410,"type":66},"2025-03-20",{"date":412,"type":21},"2027-03-03",{"name":72,"class":73},{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":421,"targetDuration":4,"studyType":22,"phases":423,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":4},"100575423","probiotic-supplementation-during-cytotoxic-chemotherapy-for-solid-tumor-malignancies-100575423","NCT06772090","Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies","A Randomized Placebo-controlled Feasibility Trial of Probiotic Supplementation During Adjuvant or Neoadjuvant Cytotoxic Chemotherapy for Solid Tumor Malignancies","Inclusion Criteria:\n\n* Adults ≥18 years old\n* Diagnosis of stage III colon cancer\n* Undergoing chemotherapeutic treatment within the MHFV or MVAHC medical systems.\n\nExclusion Criteria:\n\n* Allergy or sensitivity to probiotic supplementation\n* Diagnosis\u002Fhistory of:\n\nNon-colon GI cancer or chronic GI-related disease or disorders such as gastric ulcer, irritable bowel syndrome, inflammatory bowel disease, or intestinal malabsorption syndrome Cognitive impairment, such as dementia, or developmental disorder that would affect ability to give consent or comply with study procedures\n\n* Current treatment of cancer other than non-melanoma skin cancer, including metastases and recurrences\n* Current participation in another interventional study of medication(s)\n* Major changes in eating habits within the past 3 months, such as stopping or starting a restricted diet\n* BMI ≥40 kg\u002Fm2 or ≤17 kg\u002Fm2\n* Unexpected change in weight of ˃4.5 kg within the past 6 months",{"count":422,"type":21},40,[86],"This is a pilot single-blind placebo-controlled randomized trial to establish experimental feasibility. We plan on enrolling a pilot cohort of 40 patients, with up to 5 patients in treatment phase 0 and the remaining in treatment phase I. During Phase I, the remaining participants will be assigned to either treatment or control group using dynamic block randomization balancing on sex, age group, and disease histology.",[426,427],"Solid Tumor, Adult","Cytotoxicity","2026-02-02",{"date":430,"type":66},"2026-02-03",{"date":432,"type":21},"2026-12-25",{"date":434,"type":21},"2028-12-31",{"name":72,"class":73},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":22,"phases":445,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":450,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":74},"100547732","phase-2-rectus-sheath-block-with-liposomal-bupivacaine-versus-thoracic-epidural-analgesia-for-pain-control-following-pancreatoduodenectomy-100547732","NCT06411795","Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy","Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy: A Prospective, Randomized, Non-Inferiority Trial","Inclusion Criteria:\n\n* Adult patients, age 18 and older, undergoing open pancreaticoduodenectomy at the University of Minnesota will be included in the study\n\nExclusion Criteria:\n\n* Patients with contraindication to block placement (coagulopathy, local anesthetic allergy, infection)\n* Patients with chronic opioid use (at least 30 milligram morphine equivalents \\[MME\\] for 3 or more weeks leading up to surgery)\n* Patients unable to understand the quality of recovery survey intellectual barriers. This will be determined by the primary investigator\u002Fattending anesthesiologist's discretion\n* Patient refusal and those who have opted out of research\n* Pregnant patients - will be assessed through review of the medical record",{"count":444,"type":21},78,[24],"This phase II trial compares the effect of rectus sheath block with liposomal bupivacaine to thoracic epidural analgesia (TEA) on pain control in patients following surgical removal of all or part of the pancreas and duodenectomy (pancreatoduodenectomy). Administering long acting local anesthetics, such as liposomal bupivacaine, in between the muscle layers of the abdomen (rectus sheath block) may help with pain relief during and after surgery. TEA uses a needle to insert a flexible plastic catheter into the thoracic spine to administer anesthetic and pain medication, such as bupivacaine and hydromorphone, to treat pain in the thoracic and upper abdominal areas during and after surgery. Epidurals have been successfully used to treat pain after surgery, however, it does have a risk of low blood pressure which may limit the use in the thoracic approach. Rectus sheath blocks with liposomal bupivacaine may be as effective as TEA in reducing pain in patients following a pancreatoduodenectomy.",[448,449],"Duodenal Neoplasm","Pancreatic Neoplasm",{"date":430,"type":66},{"date":452,"type":66},"2023-11-10",{"date":454,"type":21},"2028-01-01",{"name":72,"class":73},{"id":457,"slug":4,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":81,"sex":17,"minAge":112,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":22,"phases":463,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":474,"locationsCount":74},"100538816","NCT06295757","Effects of Relighting on Smoke Toxicant Deliveries and Subjective Smoking Measures","Inclusion Criteria:\n\n* Smoking at least 10 cigarettes\u002Fday for at least 1 year (confirmed by CO \\> 8 ppm or NicAlert test of 6)\n* Engaging in relighting for at least half of their CPD\n* No smoking quit attempts in the past month nor intentions to quit in the next month\n* Stable medical or psychiatric conditions with systolic blood pressure \\\u003C 160, diastolic blood pressure \\\u003C 100 and heart rate \\\u003C 105 bpm\n\nExclusion Criteria:\n\n* Participant with current or recent alcohol or drug abuse problems, use of substances of abuse (other than marijuana due to high prevalence of co-use) within the past month\n* Currently trying or planning to quit smoking in the next month\n* Planning to become pregnant, pregnant or breastfeeding. Pregnancy exclusion will be confirmed through a urine test.",{"count":462,"type":21},30,[86],"Characterize effects of relighting on smoke toxicant deliveries and subjective smoking measures. This will be a within-subject comparison in a single experimental group of 30 smokers who report engaging in relighting behaviors. We will assess smoking intensity for relit and non-relit (i.e., smoked continuously without relighting) cigarettes in the natural environment and will conduct in-clinic measurements of smoking topography and subjective responses for relit and non-relit cigarettes. Information on relighting patterns and smoking topography collected from each participant will be used to compare machine-measured smoke yields of key harmful constituents when their usual cigarettes are smoked with and without relighting. Hypothesis: Relit cigarettes will produce higher levels of toxicants than non-relit cigarettes.",[466,467,468],"Tobacco Use","Cigarette Smoking","Nicotine Dependence",{"date":470,"type":66},"2026-02-04",{"date":472,"type":66},"2024-10-12",{"date":454,"type":21},{"name":72,"class":73},{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":482,"enrollmentInfo":483,"targetDuration":4,"studyType":22,"phases":485,"briefSummary":486,"conditions":487,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":74},"100330256","phase-2-alphabeta-tcd-hct-in-patients-with-inherited-bmf-disorders-100330256","NCT03579875","Alpha\u002FBeta TCD HCT in Patients With Inherited BMF Disorders","MT2017-17:T Cell Receptor Alpha\u002FBeta T Cell Depleted Hematopoietic Cell Transplantation in Patients With Inherited Bone Marrow Failure (BMF) Disorders","Patient Selection:\n\nInclusion Criteria:\n\nFor FA patients:\n\n* Diagnosis of Fanconi anemia\n\n  * Age \\\u003C65 years of age\n* Has one of the following risk factors:\n\n  * Severe aplastic anemia (SAA)\n  * Myelodysplastic features\n  * High risk genotype\n  * Immunodeficiency associated with history of recurrent infections\n* Karnofsky performance status ≥ 70% if ≥ 16 years of age or Lansky play score ≥ 50% for patients \\\u003C16 years of age\n\n  * Adequate pulmonary, cardiac and liver function\n  * Voluntary written consent (minor assent if appropriate) prior to the performance of any study related procedures not part of standard medical care\n\nFor TBD patients:\n\n• Diagnosis of TBD\n\n* Age \\\u003C70 years of age\n* Has one of the following risk factors:\n* Severe aplastic anemia (SAA)\n* Myelodysplastic features\n* Karnofsky performance status ≥ 70% if ≥ 16 years of age or Lansky play score\n\n  ≥ 50% for patients \\\u003C16 years of age\n* Adequate pulmonary, cardiac and liver function\n* Voluntary written consent (minor assent if appropriate) prior to the performance of any study related procedures not part of standard medical care\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding as the treatment used in this study are Pregnancy Category D. Females of childbearing potential must have a negative pregnancy test (serum or urine) within 14 days of study registration\n* Active, uncontrolled infection within 1 week prior to starting study therapy\n* Malignant solid tumor cancer within previous 2 years\n\nDonor Selection (Inclusion Criteria): meets one of the following match criteria:\n\n* an HLA-A, B, DRB1 matched sibling donor (matched sibling)\n* an HLA-A, B, DRB1 matched related donor (other than sibling)\n* a related donor mismatched at 1 HLA-A, B, C and DRB1 antigen\n* 7-8\u002F8 HLA-A,B,C,DRB1 allele matched unrelated donor per current institutional guidelines Patients and donors are typed for HLA-A and B using serological or molecular techniques and for DRB1 using high resolution molecular typing. If a donor has been selected on the basis of HLA-A, B, C and DRB1 typing as above, preference will be made for donors matched at the HLA-C locus.\n* Body weight of at least 40 kilograms and at least 12 years of age\n* Willing and able to undergo mobilized peripheral blood apheresis\n* In general good health as determined by the medical provider\n* Adequate organ function defined as:\n\n  * Hematologic: hemoglobin, WBC, platelet within 10% of upper and lower limit of normal range of test (gender based for hemoglobin)\n  * Hepatic: ALT \\\u003C 2 x upper limit of normal\n  * Renal: serum creatinine \\\u003C 1.8 mg\u002Fdl\n* Performance of a donor infectious disease screen panel including CMV Antibody, Hepatitis B Surface Antigen, Hepatitis B Core Antibody, Hepatitis C Antibody, HIV 1\u002F2 Antibody, HTLVA 1\u002F2 Antibody, Treponema, and Trypanosoma Cruzi (T. Cruzi) plus HBV, HCV, WNV, HIV by nucleic acid testing (NAT); and screening for evidence of and risks factors for infection with Zika virus, or per current standard institutional donor screen - must be negative for HIV and active hepatitis B\n* Not pregnant - females of childbearing potential must have a negative pregnancy test within 7 days of mobilization start\n* Voluntary written consent (parent\u002Fguardian and minor assent, if \\\u003C 18 years) prior to the performance of any research related procedure","65 Years",{"count":484,"type":21},48,[24],"This is a phase II trial of T cell receptor alpha\u002Fbeta depletion (α\u002Fβ TCD) peripheral blood stem cell (PBSC) transplantation in patients with inherited bone marrow failure (BMF) disorders to eliminate the need for routine graft-versus-host disease (GVHD) immune suppression leading to earlier immune recovery and potentially a reduction in the risk of severe infections after transplantation.",[488,139,312,489,490,491,492,493],"Fanconi Anemia","T Cell Receptor Alpha\u002FBeta Depletion","Telomere Biology Disorder","Bone Marrow Failure","Dyskeratosis Congenita","Telomere Biology Disorders","2026-01-29",{"date":496,"type":66},"2026-01-30",{"date":498,"type":66},"2018-11-13",{"date":500,"type":21},"2029-01-05",{"name":72,"class":73},{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":74},"100547923","evaluation-of-early-identification-of-cognitive-side-effects-of-immunotherapy-100547923","NCT06414278","Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy","Early Identification of Cognitive Side-Effects of Immunotherapy","Inclusion Criteria:\n\n* \\* ≥ 18 years of age at initiation of therapy\n\n  * Planning to undergo inpatient CAR-T therapy for primary malignancy\n  * Fluent in English (written or spoken)\n\nExclusion Criteria:\n\n* \\* Subjects with speech or hearing impediment that would make them unable to be assessed with SALSA\n\n  * Subjects with diagnosed cognitive impairment prior to CAR-T therapy\n  * Unwilling or unable to sign voluntary written consent",{"count":510,"type":21},38,"This clinical trial evaluates the use of a tool kit, Stress, Affect, Language and Speech Analysis (SALSA), for early identification of cognitive side effects of immunotherapy compared to the standard of care assessment.",[513,514],"Hematopoietic and Lymphatic System Neoplasm","Malignant Solid Neoplasm","2026-01-12",{"date":517,"type":66},"2026-01-13",{"date":519,"type":66},"2024-02-08",{"date":521,"type":21},"2028-02-21",{"name":72,"class":73},{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":22,"phases":531,"briefSummary":532,"conditions":533,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":74},"100569418","phase-1-adenovirus-rgdcradcox2f-100569418","NCT06693986","Adenovirus (RGDCRAdCOX2F)","A Phase I Study of a Tropism Modified Conditionally Replicative Adenovirus Vector (RGDCRAdCOX2F) for Endoscopic, Direct-Tumor Delivery in Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Histologically documented pancreatic adenocarcinoma that is confined to the pancreas and regional lymph nodes after staging by CT or MRI and endoscopic ultrasound.\n* One prior line of therapy is permitted (i.e. neo-adjuvant therapy); however, at least 4 weeks must have elapsed between the last dose of drug and the injection of RGDCRAdCOX2F.\n* Must be able to tolerate esophagogastroduodenoscopy (EGD) and the tumor must be accessible by endoscopic ultra sound. Participants will be excluded if obtaining biopsies are deemed unsafe or not feasible.\n* Age 18 years of age or older at the time of consent\n* Normal cardiac and pulmonary function based on history and physical exam\n* Participants with partners of childbearing potential must be willing to use at least two forms of effective birth control (one form must be a barrier method) for at least 1 month after Day 1.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding. Persons of child-bearing potential must have a negative pregnancy test (serum or urine) with 14 days of study enrollment.\n* Other pancreatic malignancies (e.g., neuroendocrine tumors and mucinous cystic) and adenocarcinomas of the ampulla, bile ducts, and duodenum.\n* Tumors in mucosal regions or close to an airway, major blood vessel, or spinal cord that in the opinion of the enrolling investigator could cause occlusion or compression in the case of tumor swelling or erosion into a major vessel in the case of necrosis.\n* Known history of human immunodeficiency virus (HIV) infection\n* Known history of or active acute or chronic active hepatitis B or C infection\n* Serious concurrent infection or medical illness, which in the enrolling investigator's opinion would jeopardize the ability of the participant to receive the treatment outlined in this protocol with reasonable safety.\n* Requires immunosuppression ≥10mg\u002Fday of prednisone for more than\n\n  1 week.\n* History of or active known or suspected autoimmune disease, or a syndrome that requires systemic or immunosuppressive agents.\n* Disease beyond the regional lymph nodes\n* Active diffuse pancreatitis\n* Active inflammatory conditions\n* Prior gastrojejunostomy",{"count":190,"type":21},[192],"This is a single center, Phase I dose finding study of a single direct tumor injection of an RGD modified conditionally replicative adenovirus (RGDCRAdcox2F) in persons with adenocarcinoma of the pancreas. The study is designed to determine the MTD of RGDCRAdCOX2F that corresponds to the maximum desired toxicity of ≤ 20%.",[534],"Adenocarcinoma of Pancreas","2026-01-05",{"date":537,"type":66},"2026-01-07",{"date":539,"type":66},"2024-12-27",{"date":541,"type":21},"2029-10-15",{"name":72,"class":73},{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":547,"acronym":4,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":549,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":551,"conditions":552,"keywords":555,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":74},"100221566","treatment-of-graft-failure-after-hematopoietic-stem-cell-transplantation-100221566","NCT02161783","Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Patients with primary or secondary graft failure, as defined below, may receive a second transplant:\n\n  * Primary graft failure is defined as not achieving an ANC ≥0.5x10\\^9\u002FL for three consecutive days by day 35 - 42 following the first transplant.\n  * Secondary graft failure is defined as achieving an ANC ≥0.5x10\\^9\u002FL for three consecutive days by day 35 - 42, but subsequently drops below 0.5x10\\^9\u002FL without recovery.\n  * Loss of chimerism is defined as achieving an ANC ≥0.5x10\\^9\u002FL for three consecutive, but with less than 10% CD15+ donor cells in the marrow or peripheral blood.\n* Recipients should have acceptable organ function defined as:\n\n  * Renal: creatinine \\\u003C 2.0 (adults) and creatinine clearance \\> 30. For creatinine clearance \\\u003C 70, consultation with a BMT pharmacist is necessary for chemotherapy dose adjustments.\n  * Hepatic: bilirubin, AST\u002FALT, ALP \\\u003C 10 x upper limit of normal\n  * Cardiac: left ventricular ejection fraction \\> 40%\n\nExclusion Criteria:\n\n* Uncontrolled infection at the time of transplant.\n* Patients with Fanconi Anemia or other DNA breakage syndromes.",{"count":550,"type":21},50,"This is a guideline for the treatment of graft failure after hematopoietic stem cell transplant (HSCT). This regimen, consisting of cyclophosphamide and fludarabine with low dose total body irradiation (TBI) is designed to promote donor engraftment by day 42 after initial graft failure.\n\nThe graft will consist of bone marrow or G-CSF mobilized peripheral blood from a haploidentical related donor. The source of stem cells will be determined by the transplant team based on factors such as patient's age, medical history, donor availability and will be according to the current University of Minnesota Blood and Marrow Transplantation Program selection guidelines.",[553,554],"Primary Graft Failure","Secondary Graft Failure",[556],"Hematopoietic stem cell transplant","2026-01-02",{"date":559,"type":66},"2026-01-06",{"date":561,"type":66},"2014-10-06",{"date":563,"type":21},"2032-01-30",{"name":72,"class":73},{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":4,"eligibilityCriteria":571,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":572,"targetDuration":4,"studyType":22,"phases":574,"briefSummary":575,"conditions":576,"keywords":578,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":74},"100465280","phase-1-study-of-pat-in-patients-with-solid-tumor-cancers-100465280","NCT05338658","Study of PAT in Patients With Solid Tumor Cancers","Phase I Study of Peptide Alarm Therapy (PAT) Administered by Intratumoral Injection With a PD-1\u002FPD-L1 Inhibitor in Patients With Solid Tumor Cancers Who Have Failed 1 or More Prior Therapies","Inclusion Criteria:\n\n* Must be seropositive for CMV and EBV.\n* Must have at least one HLA-A\\*0201 allele. This screening can be performed after determining CMV and EBV seropositivity is established or, if available, from the results of previous tumor profiling by any CLIA-certified lab (i.e. Caris, FoundationOne).\n* 18 years or older at the time of signing the pre-screening consent.\n* ECOG Performance Status 0 or 1.\n* Adequate organ function within 14 days of study enrollment\n* Cardiac: New York Heart Association (NYHA) Functional Classification Class I.\n* Pulmonary: oxygen saturation ≥ 90% on room air.\n* Time between last dose of prior anti-cancer therapy and Day 1 of this study:\n\n  * Chemotherapy: a minimum of 28 days since last treatment.\n  * Targeted therapy, immunotherapy, investigational agents: a minimum of 45 days since last dose (at least 2 months for anti-VEGF)\n  * Prior palliative radiotherapy within 7 days of start of study treatment. Participants must have recovered from all radiation-related toxicities (prior irradiation to targeted lesions is not permitted)\n* Must have recovered to CTCAE ≤Grade 1 from previous treatment related acute toxicities.\n* Persons of childbearing potential or with partners of childbearing potential must be willing to abstain from heterosexual activity or to use a highly effect form of contraception from the time of study enrollment until at least 4 months after the last dose of PD-1\u002FPD-L1 inhibitor.\n* Able to understand and provide voluntary written consent prior to the performance of any research related activity.\n\nExclusion Criteria:\n\n* Pregnant or breast feeding.\n* Requires therapeutic anticoagulation for which it is deemed unsafe to discontinue anticoagulation for 5 days prior to Cycle 1 through Day 7 of Cycle 1\n* Class II or greater New York Heart Association Functional Classification criteria or serious cardiac arrhythmias likely to increase the risk of cardiac complications of therapy (e.g. ventricular tachycardia, frequent ventricular ectopy, or supraventricular tachyarrhythmia requiring chronic therapy)\n* Known active CNS metastases\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).\n* Has received a live vaccine within 30 days prior to the first dose of study drug.\n* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to study enrollment.\n* Prior bone marrow and\u002For solid organ transplant.\n* Has severe hypersensitivity (≥Grade 3) to prior PD-1\u002FPD-L1 and\u002For any of its excipients.\n* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n* Has an active infection requiring systemic therapy.\n* Known seropositive for HIV or known active Hepatitis B or C infection with detectable viral load by PCR\n* Known history of active TB (Bacillus Tuberculosis)\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.\n* Has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, interstitial lung disease, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements in the opinion of the treating investigator.",{"count":573,"type":21},21,[192],"This is a single center Phase I study with extension of peptide alarm therapy (PAT) administered by intratumoral (IT) injection during the 1st course of a standard of care intravenous PD-1\u002FPD-L1 inhibitor for the treatment of locally advanced or metastatic solid tumor cancers that has failed to be controlled after one or more prior therapies including a previous PD-1\u002FPD-L1 inhibitor",[577,288],"Metastasis",[579],"PAT","2025-12-08",{"date":582,"type":66},"2025-12-09",{"date":584,"type":66},"2023-05-19",{"date":586,"type":21},"2027-01",{"name":72,"class":73},{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":593,"acronym":594,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":17,"minAge":596,"maxAge":597,"enrollmentInfo":598,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":600,"conditions":601,"keywords":605,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":74},"100441240","fitness-and-lung-function-among-survivors-of-heart-transplant-leukemia-and-infant-bpd-through-exercise-100441240","NCT05025774","Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise","Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant Bronchopulmonary Dysplasia (BPD, Also Known as Chronic Lung Disease of Prematurity) Through Exercise (FLASHLITE)","FLASHLITE","Inclusion Criteria:\n\n* Cases:\n\n  * Acute lymphoblastic leukemia survivor, OR living with chronic lung disease of prematurity, OR living with heart transplant\n  * 8-25 years old\n  * Height: ≥ 48 inches\n  * Ambulatory without assistance\n  * English speaking\n  * Normotensive (\\\u003C95th percentile for age; okay if managed with antihypertensive medication)\n  * SpO2 \\>92%\n  * Not pregnant\n  * ALL survivor specific: must have completed therapy ≥ 3 months prior to study entry\n* Controls\n\n  * 8-25 years old\n  * Height: ≥ 48 inches\n  * Ambulatory without assistance\n  * English speaking\n  * No history of arrhythmia or known cardiac dysfunction at baseline\n  * Normotensive (\\\u003C95th percentile for age; okay if managed with antihypertensive medication)\n  * SpO2 \\>95%\n  * Not pregnant\n\nExclusion Criteria:\n\n* Cases:\n\n  * ALL specific: received cranial radiation, bone marrow transplant recipients\n  * Investigator or patient's primary physician deems the patient unsuitable for the study\n* Controls:\n\n  * History of malignancy, CLD or HT or any other diagnosis which may reduce cardiorespiratory function\n  * Investigator deems the patient unsuitable for the study","8 Years","25 Years",{"count":599,"type":21},90,"This study aims to more accurately assess cardiac function, ventilation and exercise capacity in a non-invasive fashion, and to better characterize exercise intolerance in the setting of three populations of individuals with chronic diseases of childhood (acute lymphoblastic leukemia (ALL), chronic lung disease (CLD) of prematurity, and post-heart transplant (HT))",[602,603,29,604],"Chronic Lung Disease","Chronic Obstructive Pulmonary Disease","Heart Transplant",[606,607,608,609],"Quality of life","Lung function","Fitness","Exercise","2025-11-21",{"date":612,"type":66},"2025-11-24",{"date":614,"type":66},"2025-03-14",{"date":616,"type":21},"2026-12-01",{"name":72,"class":73},{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":623,"acronym":4,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":133,"enrollmentInfo":625,"targetDuration":4,"studyType":22,"phases":627,"briefSummary":628,"conditions":629,"keywords":632,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":639,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":74},"100295416","phase-2-auto-stem-cell-transplant-for-lymphoma-patients-100295416","NCT03125642","Auto Stem Cell Transplant for Lymphoma Patients","Autologous Stem Cell Transplant In Patients With Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL)","Inclusion Criteria:\n\n* Eligible Diseases\n\n  1. Non-Hodgkin's Lymphoma (NHL)\n\n     * Patients with chemo-sensitive histologically confirmed NHL will be eligible for this treatment protocol contingent on histologic sub-classification.\n     * Patients in partial or complete remission following cell therapy will also be eligible.\n     * NHL patients with resistant or refractory lymphoma (no PR following up to three cycles of combination chemotherapy) will not be eligible for transplant in this trial.\n     * Lymphoblastic Lymphoma:\n\n       1. All patients will be eligible in second or greater complete remission (CR) or first or subsequent partial remission (PR)\n       2. Patients with any high-risk features will be eligible in first complete remission\n       3. High risk features include: Stage IV, LDH \\>2 x upper limit of normal, ≥ 2 extranodal sites\n     * Mature B-cell Lymphoma\n\n       1. Follicular Lymphoma and other indolent lymphoma in ≥ second CR2\u002FPR2\n       2. Diffuse Large B-Cell Lymphoma: in ≥ CR2 or ≥ PR1; a high intermediate or high IPI (≥ 2 for age-adjusted IPI or ≥3 for IPI) at diagnosis and double-hit or triple-hit lymphoma will be eligible in first CR; transformed lymphoma from FL (or other indolent lymphoma) or chronic lymphocytic leukemia will be eligible if chemosensitive and bone marrow is negative\n       3. Mantle Cell Lymphoma: in first or greater CR or PR\n       4. Burkitt's\u002FBurkitt's like: all patients except localized lymphoma will be eligible any time after initial therapy (after achievement of first complete remission), or in partial remission if they fail to achieve CR; patients with localized (stage I or Ziegler stage A) will be eligible only if they fail to achieve CR1 or after relapse\n     * Mature T-Cell Lymphoma\n\n       1. Chemosensitive T-cell lymphomas including Primary T-cell not otherwise specified angioimmunoblastic, and ALK-positive anaplastic large cell, will be eligible after initial therapy, whether or not CR is achieved.\n       2. Mycosis fungoides\u002FSezary syndrome will be eligible in ≥CR2\u002FPR2\n  2. Hodgkin Lymphoma (HL)\n\n     * Patients with histologically proven HL will be eligible for transplantation after failing prior therapy.\n     * Patients with resistant disease (initial or at relapse): those who fail to achieve an objective partial response to three cycles of combination non-cross resistant chemotherapy will not be eligible for transplant in this trial.\n     * For stage I\u002FII patients treated with primary chemotherapy-radiation, they must have failed (no CR or progression after CR) at least one salvage combination chemotherapy treatment regimen\n     * For advanced (stage III\u002FIV) Hodgkin disease, patients must have failed an Adriamycin containing regimen (ABVD) or an alternative non-cross resistant regimen (e.g. MOPP)\n     * Patients with any high-risk features will also be eligible, including those who:\n\n       1. fail to achieve complete remission with initial combination chemotherapy\n       2. have bulky disease after initial therapy (chemotherapy or radiation) defined as residual mediastinal mass ≥ 5 cm or other residual mass ≥ 10 cm accompanied by other features of persisting disease (e.g., PET scan positive; high LDH; enlarging on serial x-rays or biopsy positive) will be eligible - if feasible, persistent disease should be proven by biopsy\n     * Patients should receive chemotherapy to attempt to achieve CR or minimal disease state for all patients pre-transplantation. The use of up to three cycles of non-cross resistant combination chemotherapy is advised.\n     * Residual areas of limited disease should be considered for radiotherapy after and not prior to transplantation.\n  3. HIV positive patients who are otherwise eligible for this study may be enrolled if they meet the following requirements:\n\n     * Are seen in the infectious disease (ID)\u002FHIV clinic prior to enrollment on study for the purpose of determining eligibility and for local coordination of HIV care during the peri-transplant period.\n     * Are on maximally active anti-HIV regimen to control disease as determined appropriate by the ID\u002FHIV physicians. For the majority of patients, this will be a highly active anti-retroviral therapy (HAART)-type therapy including a protease inhibitor.\n     * CD4+ ≥ 50\u002FµL\n     * HIV RNA viral load ≤ 100,000 copies per mL on each of samples 4 weeks apart. The most recent level must be within 30 days of enrollment.\n* Performance Status: Karnofsky Performance Status ≥ 80% for patients ≥ 16 years of age or Lansky Play Score ≥ 80 for patients \\\u003C 16 years of age. Note: if poor performance status is due to lymphoma - KPS ≥ 60% or LPS ≥ 60 is acceptable\n* Organ Function\n\n  1\\. No evidence of serious organ dysfunction that is not attributable to tumor including:\n  1. Hematologic:\n\n     * hemoglobin \\> 8 gm\u002FdL\n     * WBC \\> 2.5 x 109\u002FL with an ANC \\> 1.5 x 109\u002FL off G-CSF or GM-CSF for 10 days or Neulasta for 21 days\n     * platelets \\> 100 x 109\u002FL without transfusion\n     * bone marrow cellularity of \\> 20% with \\\u003C5% involvement with tumor\n  2. Renal: GFR \\> 50 ml\u002Fmin\u002F1.73m2 or serum creatinine ≤ 2.5 x ULN for age\n  3. Hepatic: no history of severe prior or ongoing chronic liver disease. Total bilirubin ≤ 2.0 mg\u002Fdl, AST and alkaline phosphatase \\\u003C5x upper limit of normal\n  4. Cardiac: free of symptoms of uncontrolled cardiac disease including unstable angina, decompensated congestive heart failure, or arrhythmia. The ejection fraction by gated cardiac blood flow scan (MUGA) or Echocardiogram must be \\>40%\n  5. Pulmonary: no significant obstructive airways disease (FEV1 must be ≥ 50%) and must have acceptable diffusion capacity (corrected DLCO \\> 50% of predicted)\n  6. Central Nervous System: Patients with a history of CNS involvement by lymphoma or with relapsed primary CNS lymphoma will be eligible for Cy\u002FTBI arm. Patients with active CNS disease are eligible if they have completed a standard treatment for CNS lymphoma and have no evidence of progressive CNS disease at the time of enrollment\n* Other Inclusion Criteria\n\n  1. At least 4 weeks from previous chemotherapy; 6 weeks from nitrosoureas\n  2. Women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment\n  3. Patients who are carriers of Hepatitis B will be included in this study\n  4. Voluntary written consent\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding: Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy\n* Eligible for any higher priority transplant protocols\n* Chemotherapy resistant disease\n* Unrelated active infection",{"count":626,"type":21},150,[24],"This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.",[630,631],"Non-Hodgkin Lymphoma","Hodgkin Lymphoma",[46,633,41,634,635,636,637],"Mature B-cell Lymphomas","Diffuse Large B-Cell Lymphoma","Mantle Cell Lymphoma","Burkitt's\u002FBurkitt's like","Mature T-Cell Lymphoma","2025-10-31",{"date":640,"type":66},"2025-11-04",{"date":642,"type":66},"2017-04-20",{"date":644,"type":21},"2027-04-30",{"name":72,"class":73},{"id":647,"slug":648,"hasResults":12,"nctId":649,"briefTitle":650,"officialTitle":651,"acronym":4,"eligibilityCriteria":652,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":653,"enrollmentInfo":654,"targetDuration":4,"studyType":22,"phases":656,"briefSummary":657,"conditions":658,"keywords":660,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":667,"lastUpdatePostDateStruct":668,"startDateStruct":670,"completionDateStruct":672,"leadSponsor":673,"locationsCount":74},"100255543","phase-2-myeloablative-consolidation-therapy-and-tandem-autologous-stem-cell-rescue-in-patients-with-high-risk-neuroblastoma-100255543","NCT02605421","Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma","Tandem Myeloablative Consolidation Therapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma","* Less than 30 years of age at diagnosis of neuroblastoma\n* End of Induction disease evaluation demonstrating CR, PR, MR or SD\n* Hematopoietic Recovery from last induction course of chemotherapy\n* No uncontrolled infection\n* Minimum frozen PBSCs of 2 x 10\\^6 CD34 cells\u002Fkg for each transplant are mandatory and a PBSC of 2 x 10\\^6 CD34 cells\u002Fkg for back-up are strongly recommended (thus, PBSC of no less than 6 x 10\\^6 CD34 cells\u002Fkg is encouraged). These must all be collected prior to the initiation of consolidation.\n* Adequate organ function defined as:\n\n  * Hepatic: AST and ALT \\\u003C 3 x upper limit of institutional normal; ALT ≤ 3 x ULN for age; total bilirubin ≤ 1.5 x ULN for age, if baseline was normal, \\> 1.0 1.5 x baseline if baseline was abnormal\n  * Cardiac: shortening fraction ≥ 27% or ejection fraction ≥ 45%, no clinical congestive heart failure\n  * Pulmonary: no evidence of dyspnea at rest and norequirement for supplemental oxygen\n  * Renal: Creatinine clearance or GFR \\> 60 mL\u002Fmin\u002F1.73m\\^2. If a creatinine clearance is performed at end induction and the result is \\\u003C 100 ml\u002Fmin\u002F1.73m\\^2, a GFR must then be performed using a nuclear blood sampling method or iothalamate clearance method. Camera method is NOT allowed as measure of GFR prior to or during Consolidation therapy for patients with GFR or creatinine clearance of \\\u003C 100 ml\u002Fmin\u002F1.73m\\^2\n* Recovery from acute toxicities of last cycle of induction chemotherapy\n* Appropriate written consent - adult or parent\u002Fguardian if patient is \\\u003C 18 years of age and minor information sheet if patient is \\> 8 years of age","30 Years",{"count":655,"type":21},12,[24],"This is a phase II single center study to administer two courses of myeloablative consolidation chemotherapy each followed by an autologous peripheral blood stem cell (PBSC) rescue in patients with high-risk neuroblastoma who have completed induction chemotherapy (independent of this study). Ideally, patients should begin consolidation chemotherapy no later than 8 weeks after the start of Induction Cycle #5; however it is strongly recommended to begin consolidation within 4-6 weeks after the start of Induction Cycle #5.",[659],"Neuroblastoma",[661,659,662,663,664,665,666],"High-risk neuroblastoma","Myeloablative chemotherapy","Myeloablative consolidation chemotherapy","Autologous peripheral blood stem cell rescue","PBSC","Autologous stem cell rescue","2025-10-20",{"date":669,"type":66},"2025-10-21",{"date":671,"type":66},"2016-06",{"date":101,"type":21},{"name":72,"class":73},""]